S. Machtens
Papers
1
Total Citations
459
H-Index
1
About
S. Machtens is a leading urologic oncologist whose research has fundamentally shaped the modern treatment landscape for prostate cancer. His primary focus lies in comparative effectiveness research, specifically evaluating the outcomes of radical therapies for localized disease. Machtens’ most impactful contribution is his seminal 2012 study, "Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy," which has garnered over 459 citations. This work provided a critical, systematic comparison of treatment modalities—including surgery and radiation—using the highly sensitive PSA endpoint, filling a major gap in the literature. By stratifying patients by risk group, Machtens enabled more personalized treatment decisions, directly influencing clinical guidelines worldwide. His research demonstrated that PSA-free survival is a powerful metric for measuring treatment effectiveness, offering patients and clinicians clearer expectations. Through this landmark analysis, Machtens has become a key voice in evidence-based urology, helping to define the standard of care for risk-adapted therapy in prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1